FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027838914> ?p ?o ?g. }

• W2027838914 endingPage "16A" @default.
• W2027838914 startingPage "1A" @default.
• W2027838914 abstract "Pulmonary arterial hypertension (PAH), which is a subset of pulmonary hypertension, is a group of diseases distinguished by vascular remodeling of the small pulmonary arteries with associated elevated pulmonary arterial pressure and right ventricular failure. This progressive and sometimes fatal disease occurs as an idiopathic disease or as a component of other disease states. Estimates of the incidence of PAH have varied from 5 to 52 cases/1 million population. Symptoms begin with shortness of breath with exertion and progress to dyspnea with normal activities and, finally, dyspnea at rest. Untreated patients with PAH have a 1-, 3-, and 5-year survival rate of 68%, 48%, and 34%, respectively. Treated, the survival rates improve to 91% to 97% after 1 year and 84% to 91% after 2 years. The current definition of PAH consists of 3 specific hemodynamic assessments confirmed by right heart catheterization findings. One of several important pathophysiologic mechanisms involved in PAH is pulmonary vascular remodeling, which is caused by endothelial and smooth muscle cell hyperproliferation. This is coincident with overexpression of the vasoconstrictor endothelin-1 and a reduction in the vasodilators nitric oxide and prostacyclin, which further impedes proper vasomotor tone, among other effects. Prostacyclin therapies augment the decreased prostacyclin levels in patients with PAH. The currently approved prostacyclins for the treatment of PAH include epoprostenol, iloprost, and treprostinil. Among the 3 medications, the delivery options include intravenous infusion, subcutaneous infusion, and inhaled formulations. Epoprostenol has been shown to have a positive effect on survival in patients with PAH. All prostacyclins have demonstrated improvements in functional class, exercise tolerance, and hemodynamics in patients with PAH. Intravenously and subcutaneously administered formulations of prostacyclins require continuous infusion pump administration, which presents clinical challenges for both the patient and the care provider. Dosing must be individualized and also presents a clinical challenge. Inhaled formulations seem efficacious in moderately symptomatic patients with PAH and might be appropriate when combined with an oral medication. Combination therapies are commonly used in clinical practice, with the decision to do so based on randomized controlled trial data and case study evidence. The present report provides an overview of PAH, the scientific rationale for treatment with prostacyclin therapy, and the benefits and risks of prostacyclin therapy, both as monotherapy and combined with other medications approved for the treatment of PAH. Pulmonary arterial hypertension (PAH), which is a subset of pulmonary hypertension, is a group of diseases distinguished by vascular remodeling of the small pulmonary arteries with associated elevated pulmonary arterial pressure and right ventricular failure. This progressive and sometimes fatal disease occurs as an idiopathic disease or as a component of other disease states. Estimates of the incidence of PAH have varied from 5 to 52 cases/1 million population. Symptoms begin with shortness of breath with exertion and progress to dyspnea with normal activities and, finally, dyspnea at rest. Untreated patients with PAH have a 1-, 3-, and 5-year survival rate of 68%, 48%, and 34%, respectively. Treated, the survival rates improve to 91% to 97% after 1 year and 84% to 91% after 2 years. The current definition of PAH consists of 3 specific hemodynamic assessments confirmed by right heart catheterization findings. One of several important pathophysiologic mechanisms involved in PAH is pulmonary vascular remodeling, which is caused by endothelial and smooth muscle cell hyperproliferation. This is coincident with overexpression of the vasoconstrictor endothelin-1 and a reduction in the vasodilators nitric oxide and prostacyclin, which further impedes proper vasomotor tone, among other effects. Prostacyclin therapies augment the decreased prostacyclin levels in patients with PAH. The currently approved prostacyclins for the treatment of PAH include epoprostenol, iloprost, and treprostinil. Among the 3 medications, the delivery options include intravenous infusion, subcutaneous infusion, and inhaled formulations. Epoprostenol has been shown to have a positive effect on survival in patients with PAH. All prostacyclins have demonstrated improvements in functional class, exercise tolerance, and hemodynamics in patients with PAH. Intravenously and subcutaneously administered formulations of prostacyclins require continuous infusion pump administration, which presents clinical challenges for both the patient and the care provider. Dosing must be individualized and also presents a clinical challenge. Inhaled formulations seem efficacious in moderately symptomatic patients with PAH and might be appropriate when combined with an oral medication. Combination therapies are commonly used in clinical practice, with the decision to do so based on randomized controlled trial data and case study evidence. The present report provides an overview of PAH, the scientific rationale for treatment with prostacyclin therapy, and the benefits and risks of prostacyclin therapy, both as monotherapy and combined with other medications approved for the treatment of PAH." @default.
• W2027838914 created "2016-06-24" @default.
• W2027838914 creator A5021150751 @default.
• W2027838914 creator A5049579219 @default.
• W2027838914 date "2013-03-01" @default.
• W2027838914 modified "2023-10-15" @default.
• W2027838914 title "Pulmonary Arterial Hypertension: New Insights Into the Optimal Role of Current and Emerging Prostacyclin Therapies" @default.
• W2027838914 cites W13250750 @default.
• W2027838914 cites W14457722 @default.
• W2027838914 cites W177395109 @default.
• W2027838914 cites W1840736932 @default.
• W2027838914 cites W1969296257 @default.
• W2027838914 cites W1984693219 @default.
• W2027838914 cites W1984778439 @default.
• W2027838914 cites W1985526821 @default.
• W2027838914 cites W1988938743 @default.
• W2027838914 cites W1990175001 @default.
• W2027838914 cites W1990400890 @default.
• W2027838914 cites W1993769725 @default.
• W2027838914 cites W1994219663 @default.
• W2027838914 cites W1997713908 @default.
• W2027838914 cites W2009411008 @default.
• W2027838914 cites W2009991668 @default.
• W2027838914 cites W2011351479 @default.
• W2027838914 cites W2011477996 @default.
• W2027838914 cites W2015018206 @default.
• W2027838914 cites W2016305001 @default.
• W2027838914 cites W2022311133 @default.
• W2027838914 cites W2023103539 @default.
• W2027838914 cites W2025593289 @default.
• W2027838914 cites W2026939372 @default.
• W2027838914 cites W2029399343 @default.
• W2027838914 cites W2029838701 @default.
• W2027838914 cites W2035384054 @default.
• W2027838914 cites W2047164601 @default.
• W2027838914 cites W2049601360 @default.
• W2027838914 cites W2057949654 @default.
• W2027838914 cites W2062249550 @default.
• W2027838914 cites W2063924018 @default.
• W2027838914 cites W2064446419 @default.
• W2027838914 cites W2064485592 @default.
• W2027838914 cites W2066295513 @default.
• W2027838914 cites W2069727305 @default.
• W2027838914 cites W2070022895 @default.
• W2027838914 cites W2076439289 @default.
• W2027838914 cites W2088616514 @default.
• W2027838914 cites W2090213540 @default.
• W2027838914 cites W2095984197 @default.
• W2027838914 cites W2096751910 @default.
• W2027838914 cites W2098537580 @default.
• W2027838914 cites W2099305762 @default.
• W2027838914 cites W2099314224 @default.
• W2027838914 cites W2100418954 @default.
• W2027838914 cites W2101768152 @default.
• W2027838914 cites W2102192501 @default.
• W2027838914 cites W2102822995 @default.
• W2027838914 cites W2102994334 @default.
• W2027838914 cites W2103563759 @default.
• W2027838914 cites W2106446798 @default.
• W2027838914 cites W2108545817 @default.
• W2027838914 cites W2109805789 @default.
• W2027838914 cites W2114863766 @default.
• W2027838914 cites W2116060557 @default.
• W2027838914 cites W2116152202 @default.
• W2027838914 cites W2116170816 @default.
• W2027838914 cites W2116673293 @default.
• W2027838914 cites W2119718845 @default.
• W2027838914 cites W2125263078 @default.
• W2027838914 cites W2128256532 @default.
• W2027838914 cites W2128701311 @default.
• W2027838914 cites W2128919501 @default.
• W2027838914 cites W2133762417 @default.
• W2027838914 cites W2133844656 @default.
• W2027838914 cites W2136203952 @default.
• W2027838914 cites W2138649273 @default.
• W2027838914 cites W2140148084 @default.
• W2027838914 cites W2141987653 @default.
• W2027838914 cites W2142743112 @default.
• W2027838914 cites W2143132974 @default.
• W2027838914 cites W2148038451 @default.
• W2027838914 cites W2148225708 @default.
• W2027838914 cites W2149688277 @default.
• W2027838914 cites W2150989458 @default.
• W2027838914 cites W2155519854 @default.
• W2027838914 cites W2155727545 @default.
• W2027838914 cites W2159677723 @default.
• W2027838914 cites W2161167348 @default.
• W2027838914 cites W2161450347 @default.
• W2027838914 cites W2162125686 @default.
• W2027838914 cites W2164435377 @default.
• W2027838914 cites W2169054361 @default.
• W2027838914 cites W2321522617 @default.
• W2027838914 cites W2329065056 @default.
• W2027838914 cites W4293178741 @default.
• W2027838914 doi "https://doi.org/10.1016/j.amjcard.2012.12.002" @default.
• W2027838914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23414683" @default.
• W2027838914 hasPublicationYear "2013" @default.
• W2027838914 type Work @default.

• next